Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6524183 | 0.85 | DHODH (0.44) | DHODHCYP11B1CYP11B2LRRK2ABL1 | |
| SCHEMBL6521013 | 0.83 | CYP2C9 (0.42) | CYP11B1CYP11B2TGFBR1MAPK14TRPA1 | |
| SCHEMBL3431442 | 0.83 | NR4A2 (0.47) | LRRK2ABL1NR4A2 | |
| Hydrochloric Acid SCHEMBL6517808 | 0.82 | CYP2C9 (0.41) | CYP11B1CYP11B2TGFBR1MAPK14TRPA1 | |
| SCHEMBL6521811 | 0.82 | TRPA1 (0.42) | CYP11B1CYP11B2LRRK2ABL1TRPA1 | |
| SCHEMBL6523033 | 0.81 | CYP11B1 (0.44) | DHODHCYP11B1CYP11B2LRRK2ABL1 | |
| SCHEMBL3430234 | 0.80 | NR1H4 (0.41) | LRRK2ABL1TGFBR1 | |
| SCHEMBL220095 | 0.78 | CYP11B1 (0.39) | CYP11B1CYP11B2TGFBR1MAPK14TRPA1 | |
| SCHEMBL2064172 | 0.78 | NR4A2 (0.55) | DHODHLRRK2ABL1NR4A2 | |
| SCHEMBL6523043 | 0.76 | CYP11B2 (0.54) | CYP11B1CYP11B2MAPK14TRPA1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262769-B1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | claimed |
| EP-2262769-B1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | JAK2, ABL1, REN | DHODH 2143/4885CYP11B1 30/4885CYP11B2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.